India, July 15 -- image credit- shutterstock

AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO), to import and distributeDurvalumab solution for infusionfor an additional indication in India.

The newly approved indication allows the use of Durvalumab in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Durvalumab as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC).

Bladder cancer is the amongst thetop 10 most common cancer worldwide, with over600,000 new casesand220,000 deathsreported globally in 2022. In India,22,500 new casesand over12,000 deathswere record...